Published in
Elsevier, Lancet Haematology, 7(4), p. e310-e316
DOI: 10.1016/s2352-3026(17)30066-2
Links
Tools
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial
Journal article published in 2017 by
Richard E. Clark,
Fotios Polydoros,
Jane F. Apperley,
Dragana Milojkovic,
Christopher Pocock,
Graeme Smith,
Jenny L. Byrne 
,
Hugues de Lavallade,
Stephen G. O'Brien,
Tony Coffey,
Letizia Foroni,
Mhairi Copland
,
Hugues de Lavallade,
Stephen G. O'Brien,
Tony Coffey,
Letizia Foroni,
Mhairi Copland
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 